Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/5-MeO-DMT/Palliative & End-of-Life Distress

5-MeO-DMT for Palliative & End-of-Life Distress

2 papers and 0 clinical trials exploring 5-meo-dmt as a treatment for palliative & end-of-life distress.

CompoundTryptamine

5-MeO-DMT

A potent tryptamine psychedelic known for profound mystical experiences, currently under clinical investigation for TRD and anxiety.

Full 5-MeO-DMT profile
IndicationApproximately 40% of patients with terminal illnesses report significant distress at the end of life.

Palliative & End-of-Life Distress

Palliative and end-of-life distress represents a significant psychosocial challenge faced by patients with life-limiting illnesses, significantly impacting quality of life. Recent research suggests that psychedelic compounds, particularly psilocybin, may offer promising therapeutic benefits in alleviating existential distress and improving psychological well-being in these patients.

Full Palliative & End-of-Life Distress profile

Academic Research

2 papers
Paywallindividual

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants

In this double-blind, placebo-controlled Phase 1 trial, intranasal BPL-003 (5‑MeO‑DMT benzoate) was well tolerated up to 12 mg and showed rapid absorption and elimination with dose‑proportional systemic exposure (Tmax ≈ 8–10 min; mean terminal half‑life <27 min) and negligible bufotenine formation. Pharmacodynamic effects scaled with plasma concentrations, producing profound, short‑lasting consciousness‑altering and mystical experiences—60% of participants had a complete mystical experience at 10–12 mg—supporting further clinical evaluation.

Published
April 14, 2024
Journal
Journal of Psychopharmacology
Authors
Rucker, J., Roberts, C. A., Seynaeve, M., Young, A. H., Suttle, B., Yamamoto, T., Ermakova, A. O., Dunbar, F., Wiegand, F.
Open Accessindividual

Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties

This cell & mice study explores the psychopharmacological profile of amino-substituted 5-MeO-tryptamines, focusing on their interactions with serotonin receptors and transporters, as well as their psychoactive and thermoregulatory properties. The study demonstrates selectivity for 5-HT1AR over 5-HT2AR among examined compounds using radioligand binding methodologies and computational docking analyses, and 5-MeO-pyr-T was identified as the most potent partial 5-HT releaser.

Published
March 14, 2024
Journal
Molecular Psychiatry
Authors
Puigseslloses, P., Nadal-Gratacós, N., Ketsela, G., Weiss, N., Berzosa, X., Estrada-Tejedor, R., Islam, M. N., Holy, M., Niello, M., Pubill, D., Camarasa, J., Escubedo, E., Sitte, H. H., López-Arnau, R.

Clinical Trials

0 trials

No clinical trials have been tagged with both 5-MeO-DMT and Palliative & End-of-Life Distress yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all 5-MeO-DMT papers Search all Palliative & End-of-Life Distress trials Full 5-MeO-DMT profile Full Palliative & End-of-Life Distress profile